GEM-231

GEM-231 is a second-generation antisense oligonucleotide consisting of an 18-mer hybrid sequence designed to target the mRNA of the RIα (regulatory subunit alpha) of cAMP-dependent protein kinase type I (PKA-I). Overexpression of PKA-I is associated with cell proliferation and transformation in cancer. By binding to RIα mRNA, GEM-231 inhibits its expression, thereby reducing PKA-I activity and exerting antitumor effects. Preclinical studies have shown that GEM-231 can inhibit tumor growth as a single agent and has synergistic or additive effects when combined with chemotherapeutic agents such as irinotecan, docetaxel, or paclitaxel. The drug was initially developed for colon cancer but has been investigated in various solid tumors. It features a mixed-backbone structure for improved metabolic stability compared to first-generation antisense oligonucleotides[1][2][7][10].